首页> 美国卫生研究院文献>Neoplasia (New York N.Y.) >HSV-1-Based Vectors for Gene Therapy of Neurological Diseases and Brain Tumors: Part II. Vector Systems and Applications
【2h】

HSV-1-Based Vectors for Gene Therapy of Neurological Diseases and Brain Tumors: Part II. Vector Systems and Applications

机译:基于HSV-1的神经疾病和脑肿瘤基因治疗载体:第二部分。向量系统及其应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Many properties of HSV-1 are especially suitable for using this virus as a vector to treat diseases affecting the central nervous system (CNS), such as Parkinson's disease or malignant gliomas. These advantageous properties include natural neurotropism, high transduction efficiency, large transgene capacity, and the ability of entering a latent state in neurons. Selective oncolysis in combination with modulation of the immune response mediated by replication-conditional HSV-1 vectors appears to be a highly promising approach in the battle against malignant glioma. Helper virus-free HSV/AAV hybrid amplicon vectors have great promise in mediating long-term gene expression in the PNS and CNS for the treatment of various neurodegenerative disorders or chronic pain. Current research focuses on the design of HSV-1-derived vectors which are targeted to certain cell types and support transcriptionally regulatable transgene expression. Here, we review the recent developments on HSV-1-based vector systems and their applications in experimental and clinical gene therapy protocols.
机译:HSV-1的许多特性特别适合将该病毒用作媒介物来治疗影响中枢神经系统(CNS)的疾病,例如帕金森氏病或恶性神经胶质瘤。这些有利的特性包括天然的向神经性,高转导效率,大的转基因能力以及进入神经元潜伏状态的能力。在对抗恶性神经胶质瘤的斗争中,选择性溶瘤结合由复制条件的HSV-1载体介导的免疫应答的调节似乎是非常有前途的方法。不含辅助病毒的HSV / AAV杂交扩增子载体有望在PNS和CNS中介导长期基因表达,以治疗各种神经退行性疾病或慢性疼痛。当前的研究集中在针对某些细胞类型并支持转录可调控的转基因表达的HSV-1衍生载体的设计上。在这里,我们回顾基于HSV-1的载体系统的最新进展及其在实验和临床基因治疗方案中的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号